Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Increased risk for other cancers in individuals with Ewing sarcoma and their relatives.

Abbott D, O'Brien S, Farnham JM, Young EL, Yap J, Jones K, Lessnick SL, Randall RL, Schiffman JD, Cannon-Albright LA.

Cancer Med. 2019 Oct 31. doi: 10.1002/cam4.2575. [Epub ahead of print]

2.

High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, Hawkins DS; Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators.

J Clin Oncol. 2019 Sep 25:JCO1900915. doi: 10.1200/JCO.19.00915. [Epub ahead of print]

PMID:
31553693
3.

Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma.

Patel PO, Pishas KI, Taslim C, Selich-Anderson J, Theisen ER, Lessnick SL.

Oncotarget. 2019 Jun 11;10(39):3865-3878. doi: 10.18632/oncotarget.26988. eCollection 2019 Jun 11.

4.

Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis.

Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL.

Genes Cancer. 2019 Feb;10(1-2):21-38. doi: 10.18632/genesandcancer.188.

5.

Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD.

Br J Cancer. 2019 Apr;120(8):869. doi: 10.1038/s41416-019-0424-7.

6.

Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.

Harlow ML, Chasse MH, Boguslawski EA, Sorensen KM, Gedminas JM, Kitchen-Goosen SM, Rothbart SB, Taslim C, Lessnick SL, Peck AS, Madaj ZB, Bowman MJ, Grohar PJ.

Clin Cancer Res. 2019 Jun 1;25(11):3417-3429. doi: 10.1158/1078-0432.CCR-18-3511. Epub 2019 Feb 5.

PMID:
30723142
7.

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.

Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N.

Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25.

8.

Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation.

Pishas KI, Lessnick SL.

Oncotarget. 2018 Nov 23;9(92):36413-36429. doi: 10.18632/oncotarget.26326. eCollection 2018 Nov 23.

9.

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD.

Br J Cancer. 2018 Aug;119(5):615-621. doi: 10.1038/s41416-018-0212-9. Epub 2018 Aug 21. Erratum in: Br J Cancer. 2019 Apr;120(8):869.

10.

Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.

Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, Pop IL, Crompton BD, Lawlor ER, Tirode F, Mora J, Delattre O, Beckerle MC, Callen DF, Sharma S, Lessnick SL.

Mol Cancer Ther. 2018 Sep;17(9):1902-1916. doi: 10.1158/1535-7163.MCT-18-0373. Epub 2018 Jul 11.

11.

Author Correction: EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.

Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR.

Nature. 2018 Jul;559(7715):E11. doi: 10.1038/s41586-018-0230-z.

PMID:
29950716
12.

EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.

Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR.

Nature. 2018 Mar 15;555(7696):387-391. doi: 10.1038/nature25748. Epub 2018 Mar 7. Erratum in: Nature. 2018 Jun 27;:.

13.

Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.

Johnson KM, Taslim C, Saund RS, Lessnick SL.

PLoS One. 2017 Nov 1;12(11):e0186275. doi: 10.1371/journal.pone.0186275. eCollection 2017.

14.

Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis.

Luo W, Xu C, Ayello J, Dela Cruz F, Rosenblum JM, Lessnick SL, Cairo MS.

Oncogene. 2018 Feb 8;37(6):798-809. doi: 10.1038/onc.2017.378. Epub 2017 Oct 23.

PMID:
29059150
15.

Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth.

Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL.

Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):9870-9875. doi: 10.1073/pnas.1701872114. Epub 2017 Aug 28.

16.

EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Tanner JM, Bensard C, Wei P, Krah NM, Schell JC, Gardiner J, Schiffman J, Lessnick SL, Rutter J.

Mol Cancer Res. 2017 Nov;15(11):1517-1530. doi: 10.1158/1541-7786.MCR-17-0182. Epub 2017 Jul 18.

17.

C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.

Gardiner JD, Abegglen LM, Huang X, Carter BE, Schackmann EA, Stucki M, Paxton CN, Lor Randall R, Amatruda JF, Putnam AR, Kovar H, Lessnick SL, Schiffman JD.

Oncotarget. 2017 Apr 18;8(16):26013-26026. doi: 10.18632/oncotarget.14847.

18.

Recent advances in targeted therapy for Ewing sarcoma.

Pishas KI, Lessnick SL.

F1000Res. 2016 Aug 25;5. pii: F1000 Faculty Rev-2077. doi: 10.12688/f1000research.8631.1. eCollection 2016. Review.

19.

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS.

Lancet Oncol. 2016 Oct;17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5. Epub 2016 Aug 25.

20.

Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.

Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL.

Oncogene. 2016 Nov 24;35(47):6155-6156. doi: 10.1038/onc.2016.142. Epub 2016 Jun 27. No abstract available.

PMID:
27345405
21.

Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.

Cash T, McIlvaine E, Krailo MD, Lessnick SL, Lawlor ER, Laack N, Sorger J, Marina N, Grier HE, Granowetter L, Womer RB, DuBois SG.

Pediatr Blood Cancer. 2016 Oct;63(10):1771-9. doi: 10.1002/pbc.26096. Epub 2016 Jun 14.

22.

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.

Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ.

Clin Cancer Res. 2016 Aug 15;22(16):4105-18. doi: 10.1158/1078-0432.CCR-15-2624. Epub 2016 Mar 15.

23.

Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.

Vo KT, Edwards JV, Epling CL, Sinclair E, Hawkins DS, Grier HE, Janeway KA, Barnette P, McIlvaine E, Krailo MD, Barkauskas DA, Matthay KK, Womer RB, Gorlick RG, Lessnick SL, Mackall CL, DuBois SG.

Clin Cancer Res. 2016 Jul 15;22(14):3643-50. doi: 10.1158/1078-0432.CCR-15-2516. Epub 2016 Feb 9.

24.

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.

Theisen ER, Pishas KI, Saund RS, Lessnick SL.

Oncotarget. 2016 Apr 5;7(14):17616-30. doi: 10.18632/oncotarget.7124. Review.

25.

EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma.

Fadul J, Bell R, Hoffman LM, Beckerle MC, Engel ME, Lessnick SL.

Genes Cancer. 2015 Mar;6(3-4):129-43.

26.

Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.

Lerman DM, Monument MJ, McIlvaine E, Liu XQ, Huang D, Monovich L, Beeler N, Gorlick RG, Marina NM, Womer RB, Bridge JA, Krailo MD, Randall RL, Lessnick SL; Children's Oncology Group Ewing Sarcoma Biology Committee.

Pediatr Blood Cancer. 2015 May;62(5):759-65. doi: 10.1002/pbc.25340. Epub 2014 Dec 2.

27.

Targeting Glutathione S-transferase M4 in Ewing sarcoma.

Zhuo R, Kosak KM, Sankar S, Wiles ET, Sun Y, Zhang J, Ayello J, Prestwich GD, Shami PJ, Cairo MS, Lessnick SL, Luo W.

Front Pediatr. 2014 Aug 6;2:83. doi: 10.3389/fped.2014.00083. eCollection 2014.

28.

Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group.

Monument MJ, Johnson KM, McIlvaine E, Abegglen L, Watkins WS, Jorde LB, Womer RB, Beeler N, Monovich L, Lawlor ER, Bridge JA, Schiffman JD, Krailo MD, Randall RL, Lessnick SL.

PLoS One. 2014 Aug 5;9(8):e104378. doi: 10.1371/journal.pone.0104378. eCollection 2014.

29.

Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.

Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL, Beckerle MC.

Mol Biol Cell. 2014 Sep 15;25(18):2695-709. doi: 10.1091/mbc.E14-01-0007. Epub 2014 Jul 23.

30.

Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, Beckerle MC, Sharma S, Lessnick SL.

Clin Cancer Res. 2014 Sep 1;20(17):4584-97. doi: 10.1158/1078-0432.CCR-14-0072. Epub 2014 Jun 24.

31.

Coordinated control of senescence by lncRNA and a novel T-box3 co-repressor complex.

Kumar P P, Emechebe U, Smith R, Franklin S, Moore B, Yandell M, Lessnick SL, Moon AM.

Elife. 2014 May 29;3. doi: 10.7554/eLife.02805.

32.

ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma.

Wiles ET, Bell R, Thomas D, Beckerle M, Lessnick SL.

Genes Cancer. 2013 Nov;4(11-12):486-500. doi: 10.1177/1947601913506115.

33.

EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma.

Sankar S, Gomez NC, Bell R, Patel M, Davis IJ, Lessnick SL, Luo W.

Genes Cancer. 2013 May;4(5-6):213-23. doi: 10.1177/1947601913489569.

34.

A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Sankar S, Tanner JM, Bell R, Chaturvedi A, Randall RL, Beckerle MC, Lessnick SL.

Mol Cell Biol. 2013 Nov;33(22):4448-60. doi: 10.1128/MCB.00241-13. Epub 2013 Sep 16.

35.

Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER; COG Ewing Sarcoma Biology Committee.

Front Oncol. 2013 Jun 6;3:141. doi: 10.3389/fonc.2013.00141. eCollection 2013.

36.

BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma.

Wiles ET, Lui-Sargent B, Bell R, Lessnick SL.

PLoS One. 2013;8(3):e59369. doi: 10.1371/journal.pone.0059369. Epub 2013 Mar 19.

37.

A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group.

Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL; COG Ewing Sarcoma Biology Committee.

Front Oncol. 2013 Mar 20;3:57. doi: 10.3389/fonc.2013.00057. eCollection 2013.

38.

Microsatellite instability in sarcoma: fact or fiction?

Monument MJ, Lessnick SL, Schiffman JD, Randall RT.

ISRN Oncol. 2012;2012:473146. doi: 10.5402/2012/473146. Epub 2012 Jul 18.

39.

Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.

Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL.

Oncogene. 2013 Oct 17;32(42):5089-100. doi: 10.1038/onc.2012.525. Epub 2012 Nov 26. Erratum in: Oncogene. 2016 Nov 24;35(47):6155-6156.

40.

The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.

Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC.

Genes Cancer. 2012 Feb;3(2):102-16. doi: 10.1177/1947601912457024.

41.

EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.

Evans CH, Liu F, Porter RM, O'Sullivan RP, Merghoub T, Lunsford EP, Robichaud K, Van Valen F, Lessnick SL, Gebhardt MC, Wells JW.

Clin Cancer Res. 2012 Oct 1;18(19):5341-51. doi: 10.1158/1078-0432.CCR-12-1985. Epub 2012 Aug 9.

42.

Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma.

Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M, Zhou H, Boucher KM, Randall RL, Jones KB, Lucas D, Rosenberg A, Thomas D, Lessnick SL, Schiffman JD.

Cancer Genet. 2012 Jul-Aug;205(7-8):391-404. doi: 10.1016/j.cancergen.2012.05.012.

43.

EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations.

Beck R, Monument MJ, Watkins WS, Smith R, Boucher KM, Schiffman JD, Jorde LB, Randall RL, Lessnick SL.

Cancer Genet. 2012 Jun;205(6):304-12. doi: 10.1016/j.cancergen.2012.04.004.

44.

The first European interdisciplinary ewing sarcoma research summit.

Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R.

Front Oncol. 2012 May 29;2:54. doi: 10.3389/fonc.2012.00054. eCollection 2012.

45.

The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm.

Spraker HL, Price SL, Chaturvedi A, Schiffman JD, Jones KB, Lessnick SL, Beckerle M, Randall RL.

Front Oncol. 2012 Jan 16;2:2. doi: 10.3389/fonc.2012.00002. eCollection 2012.

46.

Antibody detection of translocations in Ewing sarcoma.

Luo W, Milash B, Dalley B, Smith R, Zhou H, Dutrow N, Cairns BR, Lessnick SL.

EMBO Mol Med. 2012 Jun;4(6):453-61. doi: 10.1002/emmm.201200225. Epub 2012 Mar 15.

47.

Microsatellites with macro-influence in ewing sarcoma.

Monument MJ, Johnson KM, Grossmann AH, Schiffman JD, Randall RL, Lessnick SL.

Genes (Basel). 2012 Jul 23;3(3):444-60. doi: 10.3390/genes3030444.

48.

Potential for modulation of the fas apoptotic pathway by epidermal growth factor in sarcomas.

Joyner DE, Jones KB, Lessnick SL, Schiffman JD, Randall RL.

Sarcoma. 2011;2011:847409. doi: 10.1155/2011/847409. Epub 2011 Nov 1.

49.

Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Lessnick SL, Ladanyi M.

Annu Rev Pathol. 2012;7:145-59. doi: 10.1146/annurev-pathol-011110-130237. Epub 2011 Sep 19. Review.

50.

Promiscuous partnerships in Ewing's sarcoma.

Sankar S, Lessnick SL.

Cancer Genet. 2011 Jul;204(7):351-65. doi: 10.1016/j.cancergen.2011.07.008. Review.

Supplemental Content

Loading ...
Support Center